Drugs / VXX-401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05762276 | Mar 2023 → Jun 2024 | hyperlipidemia | Vaxxinity, Inc. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VXX-401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05762276 ↗ |
| Action | Inhibit | “anti-PCSK9 peptide-based immunotherapeutic candidate” NCT05762276 ↗ |
| Modality | Peptide | “a synthetic PCSK9 peptide-based immunotherapy” NCT05762276 ↗ |
| Route | Intramuscular | “administered by intramuscular (IM) injection” NCT05762276 ↗ |
| Target | PCSK9 | “anti-PCSK9 peptide-based immunotherapeutic candidate” NCT05762276 ↗ |